Arvind Srivastava

Arvind Srivastava, Ph.D., is a strategic leader currently serving as Senior Vice President of CMC at Third Arc Bio, focusing on the development of multifunctional antibodies targeting solid tumors and immune diseases. Previously, they held key roles at Eli Lilly and Company and Avantor, where they led teams in biologics development and oversaw significant process improvements, resulting in substantial cost reductions and enhanced product efficiency. With a robust background in formulation development and CMC operations, Arvind has successfully launched multiple biologics and filed over 20 INDs throughout their career. Arvind’s academic credentials include a Ph.D. in Chemistry from the Tata Institute of Fundamental Research and a Master of Science from Banaras Hindu University, with ongoing postdoctoral studies in Biochemistry at the University of North Carolina at Chapel Hill.